Cancer Family
Malignant Mesothelioma
CI-CAN-00000240Explore in graph →
Top-level96 active trials4 approved drugs11 evidence items
- NCIt
- C4456
- ICD-10
- C45
- DOID
- 1790
- MeSH
- D000086002
- MeSH
- D008654
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000240Explore in graph →
Clinical trials
478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (81)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03075527 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05070247 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors |
| terminated |
| Phase 1 / Phase 2 |
| 61 |
| TakedaINDUSTRY |
| 1 |
| Jan 22, 2026 |
| clinicaltrials |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | terminated | Phase 2 | 37 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 19, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03319537 | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | terminated | Phase 1 / Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT03502746 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | terminated | Phase 2 | 34 | Arkadiusz Z. Dudek, MDOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer | terminated | Phase 1 / Phase 2 | 37 | Kyowa Kirin Korea Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | terminated | Phase 2 | 35 | Verastem, Inc.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03393858 | Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma | terminated | Phase 1 / Phase 2 | 10 | Capital Medical UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02385812 | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma | terminated | Phase 2 | 200 | University of CalgaryOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03644550 | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT00003508 | Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma | terminated | Phase 2 | 8 | Burzynski Research InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02357147 | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)(ARTEMIS) | terminated | Phase 2 | 124 | MorphotekINDUSTRY | 6 | Mar 17, 2020 | clinicaltrials |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT03175172 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | terminated | Phase 2 | 10 | Aduro Biotech, Inc.INDUSTRY | 1 | Apr 4, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT00895648 | Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma | terminated | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00604461 | Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) | terminated | Phase 1 / Phase 2 | 13 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | terminated | Phase 2 | 344 | Verastem, Inc.INDUSTRY | 15 | Jan 30, 2017 | clinicaltrials |
| NCT01861301 | Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00597116 | An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma | terminated | Phase 2 | 25 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Oct 10, 2016 | clinicaltrials |
| NCT00165503 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT01769547 | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy(DOVE-M) | terminated | Phase 2 | 12 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00027508 | Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma | terminated | Phase 2 | — | PharmaMarINDUSTRY | 1 | Feb 24, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2026source: clinicaltrials